Alpha Tau Medical’s Innovative Prostate Cancer Therapy: Study Completion Update

Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study.

Alpha Tau Medical Ltd (DRTS) has recently completed a clinical study titled ‘A Feasibility of Neoadjuvant Interstitial Brachytherapy (Ibt) Using Diffusing Alpha Emitters Radiation Therapy (Dart) Seeds in Men With Prostate Cancer.’ The study aimed to evaluate the feasibility of using a novel cancer treatment approach involving intratumoral diffusing alpha radiation emitter devices as a neo-adjuvant therapy for prostate cancer. This innovative method could significantly impact treatment options for prostate adenocarcinoma.

The intervention tested in this study is the Diffusing Alpha Radiation Emitters Therapy (DaRT), which involves the intratumoral insertion of seeds loaded with Radium-224. These seeds release short-lived alpha-emitting atoms directly into the tumor, aiming to enhance treatment efficacy.

The study was designed as an interventional trial with a single-group model, focusing on treatment as its primary purpose. There was no masking involved in the study, meaning all participants and researchers were aware of the treatment being administered.

The study began on August 30, 2020, and has been completed with the last update submitted on December 1, 2025. These dates are crucial as they mark the progression and completion of the study, offering a timeline for potential future developments in treatment protocols.

This update could positively influence Alpha Tau Medical’s stock performance by showcasing their innovative approach in cancer treatment, potentially attracting investor interest. It also positions the company competitively within the medical device industry, particularly in oncology-focused interventions.

The study is now completed, and further details can be accessed on the ClinicalTrials portal.